Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.75 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | CLPP | Q16740 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5229773 | 0.99 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| SCHEMBL3572398 | 0.92 | CYP11B2 (0.79) | CYP11B1CYP11B2CYP3A4HPGDTSHR | |
| Hydrochloric Acid SCHEMBL3572437 | 0.91 | CYP11B2 (0.78) | CYP11B1CYP11B2CYP3A4HPGDTSHR | |
| SCHEMBL3575270 | 0.90 | CYP11B1 (0.61) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| SCHEMBL3575980 | 0.89 | CYP11B2 (0.60) | CYP11B1CYP11B2CYP19A1MDM2 | |
| Hydrochloric Acid SCHEMBL3571529 | 0.89 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| SCHEMBL8360541 | 0.89 | CYP11B2 (0.75) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| SCHEMBL3577749 | 0.88 | CYP11B1 (0.65) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3567622 | 0.88 | CYP11B2 (0.59) | CYP11B1CYP11B2CYP19A1MDM2 | |
| Hydrochloric Acid SCHEMBL3565591 | 0.87 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | claimed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | claimed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | claimed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B1 1/4885CYP11B2 6/4885CYP3A4 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.